Compare Flagstar Bank NA (FLG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Organon & Co. Common Stock — how do they compare? Flagstar Bank NA trades at $11.07 (market cap $4.65B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Flagstar Bank NA is the larger of the two by market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 23 Days and Organon & Co. Common Stock for 0 Days on average.
| FLG | OGN | |
|---|---|---|
Market Cap | $4.65B | $3.62B |
Volume | 4,101,836 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $15.36 | $13.81 |
52-Week Low | $10.72 | $5.70 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $15.19B | $11.04B |
Dividend Yield | 0.36% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.21, down 0.88% with a bearish technical outlook despite recent earnings beats in Q4 2025 and Q1 2026. The stock shows mixed fundamentals with a low P/B ratio of 0.61x but elevated P/E of 373.67x, while profitability metrics remain weak with net income margin at 2.3%. Recent news highlights strategic partnerships and a $250 million share repurchase program, though Q2 2026 earnings missed expectations.
Wall Street maintains a bullish consensus with 60% buy ratings and a $16.81 price target, representing 50% upside potential. Key risks include volatile earnings performance, high valuation multiples, and negative cash flow trends. The company's turnaround efforts and strong capital position provide potential catalysts, but execution risks remain significant.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
